Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jinhua Xiaocuo Granules (金花消痤颗粒) is an approved traditional Chinese medicine (TCM) formulated as granules for oral administration. Developed and manufactured by companies including Shanghai Huayuan Anhui Renji Pharmaceutical and Shanghai Huayuan Anhui Guangsheng Pharmaceutical, it is primarily indicated for the treatment of acne vulgaris (acne) associated with 'heat in the lungs and stomach' according to TCM theory. The formulation consists of a mixture of nine herbal ingredients: Gardenia jasminoides fruit (炒栀子), Lonicera japonica flower (金银花), Scutellaria baicalensis root (炒黄芩), Rheum palmatum root and rhizome (酒炙大黄), Coptis chinensis rhizome (黄连), Platycodon grandiflorus root (桔梗), Mentha haplocalyx (薄荷), Phellodendron amurense bark (黄柏), and Glycyrrhiza uralensis root (甘草). It exerts its therapeutic effects through clearing heat, purging fire, detoxifying, and reducing swelling, which helps alleviate inflammatory acne lesions, sore throat, mouth ulcers, and constipation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on jinhua xiaocuo granules.